HIV mutation literature information.


  Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
 PMID: 14990731       2004       Journal of virology
Abstract: The active-site expansion includes position 82 and 84 mutations due to the alterations in the amino acid side chains from longer to shorter (e.g., V82A and I84V).


  Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine.
 PMID: 14999613       2004       The Journal of infectious diseases
Abstract: One had evidence of V82A in 9 of 30 clones at week 24, with no increase at week 40.


  A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution.
 PMID: 15056001       2004       Journal of medicinal chemistry
Abstract: A structural mechanism for the unimpaired inhibition of the protease Val82Ala mutant is also suggested, based on energy calculations and analyses.


  A Comparative Molecular Dynamics, MM-PBSA and Thermodynamic Integration Study of Saquinavir Complexes with Wild-Type HIV-1 PR and L10I, G48V, L63P, A71V, G73S, V82A and I84V Single Mutants.
 PMID: 15066177       2004       European journal of biochemistry
Abstract: PR(V82A) showed local changes in residues 81-82 at the site of the mutation, while PR(L90M) showed local changes near Met90 and an additional interaction with indinavir.
Abstract: The crystal structures of the wild-type HIV-1 protease (PR) and the two resistant variants, PR(V82A) and PR(L90M), have been determined in complex with the antiviral drug, indinavir, to gain insight into the molecular basis of drug resistance.
Abstract: The inhibition (K(i)) of PR(V82A) and PR(L90M) was 3.3- and


  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.
 PMID: 15066436       2004       Journal of molecular biology
Abstract
Abstract: PR(V82A) showed differences in the position of the main-chain atoms of residue 82 compared to PR structure that better accommodated the inhibitor.
Abstract: Finally, the 1.10A resolution structure of PR(V82A) with UIC-94017 showed an unusual distribution of electron density for the catalytic aspartate residues, which is discussed in relation to the reaction mechanism.


  Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
 PMID: 15134184       2004       Antiviral therapy
Abstract: Insertions (P459Ins) within p6 protein, leading to partial or complete duplication of the PTAPP motif, were significantly associated with a decreased VR (P459Ins versus wild-type; -0.3 +/- 0.8 vs -1.1 +/- 1.2 log copies/ml, P=0.007) and were more frequent when the V82A/F/T/S PR mutation was present (P=0.020).


  Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
 PMID: 15155216       2004       Antimicrobial agents and chemotherapy
Abstract: Other mutations were L10I/V, K20R, M46I, V82A/I, I84V, N88D, and N88S.


  Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.
 PMID: 15168798       2004       Antiviral research
Abstract: Other amino acid substitutions, i.e., L10I, I54V, L63P, A71V and V82A, were well retained (t(1/2) > 36 days).


  Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.
 PMID: 15257882       2004       European journal of medical research
Abstract: 10.5% showed mutations indicating nucleoside reverse transcriptase inhibitor- (NRTI) resistance (M41L, E44D, D67N, T69D/N, L74V, V118I, M184V, L210W, K219Q), 2.8% showed non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance (K103N, V108I, Y181C), and 2.1% showed protease-inhibitor- (PI) associated resistance (


  The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
 PMID: 15259893       2004       Antiviral therapy
Abstract: HIV variants resistant to saquinavir and ritonavir usually contain L90M and V82A substitutions, respectively.



Browser Board

 Co-occurred Entities




   Filtrator